Garsorasib, Benmelstobart, Anlotinib + Benmelstobart, Anlotinib + Garsorasib, Cetuximab Beta Injection
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Local Advanced or Metastatic NSCLC
Conditions
Local Advanced or Metastatic NSCLC
Trial Timeline
Dec 23, 2025 → Dec 30, 2028
NCT ID
NCT07294261About Garsorasib, Benmelstobart, Anlotinib + Benmelstobart, Anlotinib + Garsorasib, Cetuximab Beta Injection
Garsorasib, Benmelstobart, Anlotinib + Benmelstobart, Anlotinib + Garsorasib, Cetuximab Beta Injection is a phase 2 stage product being developed by Sun Pharmaceutical for Local Advanced or Metastatic NSCLC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07294261. Target conditions include Local Advanced or Metastatic NSCLC.
What happened to similar drugs?
6 of 20 similar drugs in Local Advanced or Metastatic NSCLC were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07294261 | Phase 2 | Recruiting |
Competing Products
20 competing products in Local Advanced or Metastatic NSCLC